Free Trial
ASX:MSB

Mesoblast (MSB) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
10.19 million shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
2.58%
Price Target
N/A
MSB stock logo

About Mesoblast Stock (ASX:MSB)

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

MSB Stock News Headlines

MESO Mar 2024 3.000 put
MESO Mar 2024 2.000 put
Mesabi Trust MSB
When Will Mesoblast Limited (ASX:MSB) Breakeven?
See More Headlines
Receive MSB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2019
Today
5/21/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
83
Year Founded
N/A

Profitability

Net Income
$-73,060,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$7.47 million
Book Value
A$0.50 per share

Miscellaneous

Outstanding Shares
1,140,000,000
Free Float
N/A
Optionable
Not Optionable
Beta
2.42
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Silviu Itescu FACP (Age 67)
    FACRA, FRACP, MBBS (Hons), Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director
    Comp: $1.13M
  • Dr. Eric A. Rose M.D. (Age 73)
    Chief Medical Officer & Executive Director
    Comp: $956.61k
  • Mr. Andrew Chaponnel B.Com.
    Interim Chief Finance Officer
  • Mr. Peter T. Howard B.Sc. (Age 56)
    L.L.B., LLB (Hons), General Counsel & Corporate Executive
  • Mr. Roger D. Brown BA
    Head of Spinal Orthopedic Disorders
  • Mr. Michael Schuster BSc (Age 47)
    M.B.A., MS, Head of Pharma Partnering
  • Ms. Geraldine Storton B.Sc.
    M.B.A., MMS, Head of Regulatory Affairs & Quality Management
  • Mr. Justin Horst B.S.
    Head of Manufacturing
  • Ms. Niva Sivakumar B.Com.
    L.L.B., Joint Company Secretary
  • Mr. Paul Hughes BPHARM
    Joint Company Secretary

MSB Stock Analysis - Frequently Asked Questions

How were Mesoblast's earnings last quarter?

Mesoblast Limited (ASX:MSB) issued its quarterly earnings data on Thursday, February, 21st. The company reported ($0.09) EPS for the quarter.

What other stocks do shareholders of Mesoblast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Mesoblast (MESO), Alliance Resource Partners (ARLP), OceanaGold (OGC), Bubs Australia (BUB), Genfit (GNFT), Pluristem Therapeutics (PSTI), Starpharma (SPL), Viking Therapeutics (VKTX), Alkane Resources (ALK) and Alcidion Group (ALC).

This page (ASX:MSB) was last updated on 5/21/2024 by MarketBeat.com Staff

From Our Partners